Victory Capital Management Inc. Raises Stake in Omnicell, Inc. (NASDAQ:OMCL)

Victory Capital Management Inc. lifted its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 11,982.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,148,426 shares of the company's stock after acquiring an additional 1,138,921 shares during the quarter. Victory Capital Management Inc. owned 2.50% of Omnicell worth $50,071,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in OMCL. Vanguard Group Inc. lifted its holdings in Omnicell by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company's stock valued at $165,200,000 after acquiring an additional 80,312 shares during the period. Assenagon Asset Management S.A. grew its position in Omnicell by 61.3% during the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company's stock valued at $16,240,000 after buying an additional 228,093 shares during the period. SG Americas Securities LLC acquired a new stake in Omnicell during the first quarter valued at $684,000. Federated Hermes Inc. increased its holdings in Omnicell by 1,113.6% in the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company's stock valued at $26,830,000 after buying an additional 909,480 shares in the last quarter. Finally, Connors Investor Services Inc. raised its position in shares of Omnicell by 64.6% in the first quarter. Connors Investor Services Inc. now owns 95,547 shares of the company's stock worth $2,793,000 after acquiring an additional 37,502 shares during the period. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Trading Down 2.0 %

OMCL traded down $0.93 on Friday, hitting $45.67. 412,855 shares of the company's stock were exchanged, compared to its average volume of 526,537. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.74. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -117.10, a P/E/G ratio of 46.03 and a beta of 0.81. The firm has a 50-day moving average price of $44.20 and a 200-day moving average price of $36.82.

Wall Street Analyst Weigh In

A number of research firms have recently commented on OMCL. Craig Hallum raised their target price on Omnicell from $45.00 to $64.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Barclays raised their price objective on Omnicell from $39.00 to $58.00 and gave the company an "equal weight" rating in a report on Thursday, October 31st. Bank of America reaffirmed a "neutral" rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Wells Fargo & Company boosted their price target on shares of Omnicell from $30.00 to $41.00 and gave the stock an "equal weight" rating in a report on Monday, October 14th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Omnicell from $26.00 to $37.00 and gave the stock a "neutral" rating in a research report on Friday, August 23rd. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $50.83.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.